About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

K Pharma,Inc.(4896) Summary

4896
TSE Growth
K Pharma,Inc.
751
JPY
+87
(+13.10%)
Apr 10, 3:30 pm JST
5.11
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
739
Apr 10, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.86
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 10, 2025
Opening Apr 10, 9:09 am
700 JPY 4.75 USD
Previous Close Apr 9
664 JPY 4.56 USD
High Apr 10, 3:30 pm
751 JPY 5.11 USD
Low Apr 10, 9:11 am
650 JPY 4.41 USD
Volume
934,100
Trading Value
0.65B JPY 4.43M USD
VWAP
695.93 JPY 4.74 USD
Minimum Trading Value
75,100 JPY 511 USD
Market Cap
8.72B JPY 0.06B USD
Number of Trades
2,535
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
Mid
1-Year Average
254
1-Year High Mar 26, 2025
14,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 2,000 562,300 281.15
Mar 28, 2025 0 603,200
Mar 21, 2025 0 124,800
Mar 14, 2025 0 122,200
Mar 7, 2025 0 116,400
Company Profile
K Pharma, Inc. engages in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company originated from Keio University.
Sector
Pharmaceuticals
K Pharma, Inc. is a company specializing in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company primarily focuses on the central nervous system disease area, developing both iPS cell-based drug discovery and regenerative medicine businesses. In iPS drug discovery, K Pharma is advancing the development of treatments for intractable diseases such as ALS and Alzheimer's disease. In regenerative medicine, the company is working on developing iPS cell-derived neural progenitor cell transplantation therapies for neurological disorders like spinal cord injury and cerebral infarction. Through collaborations with universities and research institutions, K Pharma commercializes basic research findings and has established a revenue model based on licensing agreements with pharmaceutical companies. The company aims for early clinical application, promoting the development of groundbreaking treatments in areas with high unmet medical needs.